In this issue:
Pembrolizumab vs chemotherapy in PD-L1-expressing NSCLC
SC trastuzumab for ERBB2-positive early breast cancer
Pertuzumab + trastuzumab for HER2-amplified metastatic colorectal cancer
Polatuzumab vedotin + immunochemotherapy in DLBCL
Trastuzumab deruxtecan in advanced HER2-positive gastric cancer
Ibrutinib in non-germinal centre B-cell DLBCL
Dosing regimens for nivolumab + ipilimumab for advanced melanoma
Daratumumab for newly diagnosed multiple myeloma
Pembrolizumab in previously treated mTNBC
Pembrolizumab in untreated PD-L1-positive mTNBC
Please login below to download this issue (PDF)